北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
作者: Wang, Fen; Wang, Shuhang; Wang, Zhijie; Duan, Jianchun; An, Tongtong; Zhao, Jun; Bai, Hua; Wang, Jie
关键词: EGFR phosphorylation ; EGFR mutation ; Non-small cell lung cancer
刊名: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
发表日期: 2012-08-18
DOI: 10.1186/1756-9966-31-65
卷: 31
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: GROWTH-FACTOR RECEPTOR ; CELL LUNG-CANCER ; TYROSINE KINASE DOMAIN ; PULMONARY ADENOCARCINOMA ; MOLECULAR PREDICTORS ; ACTIVATING MUTATIONS ; POOR-PROGNOSIS ; ERBB RECEPTORS ; TUMOR RESPONSE ; GEFITINIB
英文摘要:

Background: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% of patients with EGFR wild-type are responsive to TKIs, suggesting that other determinants of outcome besides EGFR mutation might exist. We hypothesized that activation of phosphorylated EGFR could be a potential predictive biomarker to EGFR-TKIs treatment among patients in wild-type EGFR.

Method: Total of 205 stage IIIb and IV NSCLC patients, tissue samples of whom were available for molecular analysis, were enrolled in this study. The phosphorylation of EGFR at tyrosine 1068 (pTyr1068) and 1173 (pTyr1173) were assessed by immunohistochemistry, and EGFR mutations were detected by denaturing high performance liquid chromatograph (DHPLC).

Results: Among 205 patients assessable for EGFR mutation and phosphorylation analysis, 92 (44.9%) were EGFR mutant and 165 patients (57.6%) had pTyr1173 expression. Superior progression-free survival (PFS) was seen after EGFR-TKIs therapy in patients with pTyr1068 expression compared to pTyr1068 negative ones (median PFS 7.0 months vs. 1.2 months, P < 0.001). Inversely, patients with pTyr1173 had a shorter PFS (4.8 months VS. 7.7 months, P = 0.016). In subgroup of patients with wild-type EGFR, pTyr1068 expression positive ones had a significantly prolonged PFS (4.2 months vs. 1.2 months P < 0.001) compared with those without pTyr1068 expression. Sixteen patients with both wild-type EGFR and pTyr1068 who responded to EGFR-TKIs had median PFS of 15.6 months (95% CI: 7.28-23.9).

Conclusion: pTyr1068 may be a predictive biomarker for screening the population for clinical response to EGFR-TKIs treatment; especially for patients with wild-type EGFR.

语种: 英语
所属项目编号: 30772472
项目资助者: China National Funds for Distinguished Young Scientists ; Capital Development Foundation
WOS记录号: WOS:000313890400001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64480
Appears in Collections:北京大学临床肿瘤学院_胸部肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Dept Thorac Med Oncol, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100036, Peoples R China

Recommended Citation:
Wang, Fen,Wang, Shuhang,Wang, Zhijie,et al. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR[J]. JOURNAL OF EXPERIMENTAL &amp; CLINICAL CANCER RESEARCH,2012,31.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wang, Fen]'s Articles
[Wang, Shuhang]'s Articles
[Wang, Zhijie]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wang, Fen]‘s Articles
[Wang, Shuhang]‘s Articles
[Wang, Zhijie]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace